Skip to content
    NVEC
    Earnings call· Jun 2026(Q1 FY27)

    NVE CORP /NEW/ NVEC

    Jul 22, 2026 Source

    Executive summary

    NVE Corporation Q1 FY27 — Exceptional Revenue and Net Income Growth

    NVE Corporation reported exceptional Q1 FY27 results, with significant revenue and net income growth driven by new product sales and a strong semiconductor market. Management expressed optimism about future growth, attributing it to a validated strategy targeting high-growth markets like robotics and AIoT, new products, and recently expanded capacity, despite refraining from specific forward guidance.

    Highlights

    5
    • Total revenue increased 81% to $11 million, driven by new product sales and a strong semiconductor market.

    • Net income increased 79% to $6.39 million, resulting in $1.32 diluted EPS.

    • Gross margin improved to 81.3% of revenue, up from 80.6% in the prior year quarter.

    • Operating margin was 66%, pretax margin was 78%, and net margin was 58%.

    • Cash plus marketable securities increased $391,000 to $43.9 million as of June 30, 2026.

    Concerns

    2
    • Interest income decreased 10% due to a reduction in the marketable securities portfolio.

    • Total expenses increased 49%, driven by a 31% increase in R&D and an 81% increase in SG&A.

    Guidance & targets

    1
    CategoryTargetConfidence
    Fixed asset purchases
    significantly less than the prior year
    medium materiality
    High

    Operational metrics

    18
    Total revenue growth
    81%YoY
    Q1 FY27

    Total revenue increased to $11 million from $6.1 million in the prior year quarter.

    Product sales growth
    82%YoY
    Q1 FY27

    Product sales increased across defense and nondefense product lines as well as distributor and direct channels.

    Contract R&D revenue growth
    53%YoY
    Q1 FY27

    Increase in contract R&D revenue.

    GAAP gross margin
    81.3%up from 80.6%
    Q1 FY27

    Higher volumes helped boost gross margin compared to the prior year quarter.

    Total expenses growth
    49%YoY
    Q1 FY27

    Total expenses increased due to R&D and SG&A increases.

    Research and development expense growth
    31%YoY
    Q1 FY27

    Increase due to increased staffing and new product development activities.

    Selling, general and administrative expense growth
    81%YoY
    Q1 FY27

    Primarily due to increased performance-based compensation.

    Expenses as percentage of revenue
    15%down from 19%
    Q1 FY27

    The increase in expenses was less than the revenue increase.

    Interest income change
    -10%YoY
    Q1 FY27

    Due to decrease in marketable securities portfolio as proceeds from bond maturities partially funded dividends and fixed asset purchases in the prior fiscal year.

    Net income growth
    79%YoY
    Q1 FY27

    Net income increased to $6.39 million from $3.58 million in the prior year quarter.

    Diluted EPS
    $1.32up from $0.74
    Q1 FY27

    Diluted earnings per share for the quarter.

    Operating margin
    66%
    Q1 FY27

    Profitability metric for the quarter.

    Pretax margin
    78%
    Q1 FY27

    Profitability metric for the quarter.

    Net margin
    58%
    Q1 FY27

    Profitability metric for the quarter.

    Fixed asset purchases
    $57,000down from $1.06 million
    Q1 FY27

    The decrease was due to the completion of our 2-year multimillion dollar expansion.

    Cash and marketable securities balance
    $43.9 millionup $391,000
    Q1 FY27

    As of June 30, 2026, compared to $43.5 million as of March 31.

    Accounts receivable
    increased
    Q1 FY27

    Accounts receivable did increase, and most of that increase is driven by increased sales in the past quarter. Timing of customer payments as well contributed some of that, but mostly driven by increased sales in the past quarter. Analyst noted it went up 'not quite double'.

    Quarterly dividend
    $1covered for the second consecutive quarter
    Q1 FY27

    Earnings more than covered our $1 per share quarterly dividend for the second consecutive quarter.

    Industry KPIs

    2
    MetricValueDetails
    Fab capacity utilization
    Inventory channel inventorydecreased 6%%

    Product announcements

    1
    ProductTypeDetails
    2 new wafer-level chip scale sensors for implantable medical deviceslaunch

    Capital programs

    1
    Capacity expansioncompletedmultimillion dollar
    Period spend: $57,000
    Spent to date: $1.06 million (Q1 FY26)
    Funding: proceeds from bond maturities (prior fiscal year)
    Start: Q1 FY25 (implied)

    Benefit: Capacity for R&D activities and volume production for new products

    The decrease in fixed asset purchases was due to the completion of our 2-year multimillion dollar expansion. The expanded capacity is now being phased into volume production for new products.

    Risks & headwinds

    5
    Reliance on several large customers

    significant percentage of revenue

    Economic environment uncertainties

    uncertainties related to the economic environments in the industries we serve

    Future sales and revenues uncertainties

    uncertainties related to future sales and revenues

    Decreased interest incomeQ1 FY27

    decreased 10%

    Mitigation: Decrease in marketable securities portfolio due to funding dividends and fixed asset purchases in prior fiscal year.

    Historical revenue run rate reversionpast

    historical $25 million annualized revenue run rate

    Mitigation: Management is optimistic that current quarter represents a new, higher plateau due to validated strategy, new products, and expanded capacity, but does not provide specific forward guidance.

    What to watch in Q2 FY27

    5

    Revenue run rate sustainability

    next earnings call in October
    Current$11 million in Q1 FY27
    Targetnew higher, meaningfully higher plateau

    Why it matters

    To confirm if the 'blowout quarter' represents a sustainable shift from historical revenue patterns and validates the new strategy.

    Very importantly, can you speak to the possibility or the likelihood that this represents a new higher, meaningfully higher plateau and over the next 3 to 5 years, a major increase, hopefully💬, in strong double digits in the company's secular revenue growth rate.

    Q&A highlights

    8

    How much of the sequential revenue increase can be attributed to capacity expansion versus market demand?

    Both capacity expansion and strong market conditions contributed to the growth. The recently completed expansion is being used for R&D and new product production, while new products in important markets are also driving growth.

    We see both as factors. We've recently completed the expansion that you mentioned, and we started using that capacity primarily for R&D activities. But we also see the market conditions as important factors.

    asked by [ Ittai ] from Principal Financial · answered by Peter Eames

    2 min read5 chapters

    Detailed Narrative

    01

    Q1 FY27 Financial Highlights

    NVE Corporation reported a strong first quarter for FY27, with total revenue surging 81% year-over-year to $11 million. This growth was primarily fueled by an 82% increase in product sales and a 53% increase in contract R&D revenue. Net income saw a substantial 79% rise to $6.39 million, translating to $1.32 per diluted share. Profitability metrics were robust, with gross margin expanding to 81.3% (up from 80.6%), operating margin at 66%, pretax margin at 78%, and net margin at 58%.

    02

    New Product Launches and R&D Focus

    The company launched two new wafer-level chip scale sensors for implantable medical devices, which are approximately one-third the size of conventionally packaged versions. These new sensors feature a unique MRI-safe capability, remaining stable in magnetic fields over 9 Tesla. NVE's R&D strategy is focused on high-value markets such as advanced humanoid robotics, data centers, and AIoT, with ongoing development of more precise sensors for robotics and power-efficient isolators for power conversion.

    03

    Market Strategy and Sales Initiatives

    NVE actively participated in two major sensor trade shows, Sensors Converge in Silicon Valley and Sensor+ Test in Germany, to promote its products for robotics, AIoT, and power conversion. Management believes these investments will translate into future sales, particularly highlighting robotics as the strongest growing and most promising market due to the low power and precision advantages of NVE's technologies. The company noted new products are being adopted by both existing and new customers.

    04

    Leadership Transition and Board Expansion

    President and CEO Daniel Baker announced his retirement, effective at the annual meeting in August, with Pete Eames appointed as his successor. Baker will transition to Chairman of the Board, and the Board will expand from five to seven directors, with Pete Eames and Carolyn Valentine joining. This expansion is intended to strengthen corporate governance, building on the company's existing high ISS governance score.

    05

    Capacity Expansion and Balance Sheet Strength

    NVE completed a two-year multimillion-dollar capacity expansion, which is now being phased into volume production for new products after initial use for R&D. Fixed asset purchases for the quarter were significantly lower at $57,000, compared to $1.06 million in the prior year, reflecting the completion of this expansion. The balance sheet strengthened, with cash plus marketable securities increasing to $43.9 million as of June 30, 2026, and inventories decreasing 6% due to increased product sales.

    AI-generated summary of the company’s earnings call. Not investment advice.